 Connection
Mark Boguniewicz to Drug Industry
This is a "connection" page, showing publications Mark Boguniewicz has written about Drug Industry.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.190 |
|
|
|
-
Siegfried EC, Jaworski JC, Eichenfield LF, Paller A, Hebert AA, Simpson EL, Altman E, Arena C, Blauvelt A, Block J, Boguniewicz M, Chen S, Cordoro K, Hanna D, Horii K, Hultsch T, Lee J, Leung DY, Lio P, Milner J, Omachi T, Schneider C, Schneider L, Sidbury R, Smith T, Sugarman J, Taha S, Tofte S, Tollefson M, Tom WL, West DP, Whitney L, Zane L. Developing drugs for treatment of atopic dermatitis in children (=3 months to <18 years of age): Draft guidance for industry. Pediatr Dermatol. 2018 May; 35(3):303-322.
Score: 0.137
-
Prendergast MM, Abramovits W, Boguniewicz M, Lebwohl M, Tokar M, Tong KB. Look beyond financial conflicts of interest in evaluating industry-academia collaborations in burden-of-illness and outcomes research studies in dermatology. J Invest Dermatol. 2004 Sep; 123(3):452-4.
Score: 0.053
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|